IFNL3 and fibrosis: Moreover, in those countries where PI are already being administered, the triple therapy may not be appropriate for all patients; naïve patients with the IL28B-C/C genotype and F0–F2 fibrosis stage may still be treated with PegIFN-α plus RBV [26].